Tatsuki Ikoma

Kobe University Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (7)

Nobuhiro Shibata

Lecturer

Kansai Medical University

JAPAN

View details

Sohei Satoi

Kansai Medical University

JAPAN

View details

Tomohisa Yamamoto

Kansai Medical University

JAPAN

View details

Takayasu Kurata

JAPAN

View details

Naoki Furuya

Ohio State University

UNITED STATES

View details

Shogen Boku

Lecturer

Osaka University Hospital

JAPAN

View details

Daisuke Hashimoto

Kansai Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tatsuki Ikoma

Research Interests

Explore related searches

Contact this professor

Articles (12)

Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck

Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer

Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III <i>BRAF</i> V600E-mutated colorectal cancer

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Collaborators (7)

Nobuhiro Shibata

Sohei Satoi

Tomohisa Yamamoto

Takayasu Kurata

Naoki Furuya

Shogen Boku

Daisuke Hashimoto

Make your next move.